Clinical Trial Update: MAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects (Wallaby) [Phase 1]

View source ↗

Summary

Phase 1 Wallaby trial evaluating intravitreal VP-001 in PRPF31 mutation–associated retinal dystrophy has completed the dose-ranging maximum tolerated dose asses…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Retinitis Pigmentosa 11

Drugs mentioned

• VP-001

Snippet

Sponsor: PYC Therapeutics | Conditions: Retinitis Pigmentosa 11, Retinal Degeneration | Phase 1 | Status: COMPLETED